3 completed, 1 recruiting, 1 terminated. 4 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Terminated 1 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
| Phase 1 | 1 | Completed 1 |
Follow Activated PI3K-delta Syndrome: new trials by email Literature Review of Activated PI3K-delta Syndrome trials Research Report on Activated PI3K-delta Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| New Biomarker-based Strategy to Screen and Monitor for Activated Phosphoinositide 3-kinase δ Syndrome Blood samples, Urine samples, Stool samples - Activated PI3K Delta Syndrome | Recruiting | Assistance Publique - Hôpitaux de Paris | 14 | 2025-06-26 | 2026-03-23 | |
| Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome Rapamycin - Activated PI3K-delta Syndrome, Immunodeficiency Primary | Phase 1 / Phase 2 | Completed | Children's Hospital of Fudan University | 30 | 2017-12-01 | 2024-07-09 |
| Extension to the Study of Efficacy of CDZ173 in Patients With APDS/PASLI CDZ173 - Activated PI3Kdelta Syndrome (APDS); PASLI Disease | Phase 2 / Phase 3 | Terminated | Pharming Technologies B.V. | 37 | 2016-09-08 | 2026-03-30 |
| Safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Repeat Doses of Inhaled Nemiralisib in Patients With APDS/PASLI Nemiralisib - Activated PI3K-delta Syndrome | Phase 2 | Completed | GlaxoSmithKline | 5 | 2016-07-22 | 2021-06-18 |
| Study of Efficacy of CDZ173 in Patients With APDS/PASLI CDZ173, Placebo - Common Variable Immunodeficiency (CVID), APDS / PASLI | Phase 2 / Phase 3 | Completed | Novartis Pharmaceuticals | 37 | 2015-08-24 | 2022-08-10 |
Common Variable Immunodeficiency (1) · Immunologic Deficiency Syndromes (1) · Lymphadenopathy (1) · Primary Immunodeficiency Diseases (1)
Immune System Diseases (3) · Immunologic Deficiency Syndromes (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Genetic Diseases, Inborn (1) · Hemic and Lymphatic Diseases (1) · Lymphatic Diseases (1)
leniolisib (2) · Blood Specimen Collection (1) · Nemiralisib (1) · Sirolimus (1)
Assistance Publique - Hôpitaux de Paris (1) · Children's Hospital of Fudan University (1) · GlaxoSmithKline (1) · Novartis Pharmaceuticals (1) · Pharming Technologies B.V. (1)
Belarus (2) · Czechia (2) · Germany (2) · Italy (2) · Netherlands (2) · Russia (2) · United Kingdom (2) · United States (2) · China (1) · France (1) · Ireland (1)
Jinqiao Sun, Ph.D.,M.D (1) · Koneti V Rao, MD (1) · Sven Kracker, PHD (1) · Virgil Dalm, MD (1)
PMID 28972011, PMID 36399712, PMID 37797893, PMID 38593221, PMID 41091701
2014 (1), 2015 (1), 2016 (1)